Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 475

The DOI matches its Crossref record.

Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B

Cooksley, W. G. E., Piratvisuth, T., Lee, S.‐D., Mahachai, V., Chao, Y.‐C., Tanwandee, T., Chutaputti, A., Chang, W. Yu, Zahm, F. E., Pluck, N.·2003·Journal of Viral Hepatitis

Abstract

Summary.: Current therapies for chronic hepatitis B (CHB) have a number of limitations, and better treatment options are needed. Peginterferon α‐2a (40 kDa) is superior to conventional interferon α‐2a in the treatment of chronic hepatitis C. This is the first report on peginterferon α‐2a (40 kDa) in the treatment of CHB. In this phase II study, 194 patients with CHB not previously treated with conventional interferon‐α were randomized to receive weekly subcutaneous doses of peginterferon α‐2a (40 kDa) 90, 180 or 270 μ g, or conventional interferon α‐2a 4.5 MIU three times weekly. Twenty‐four weeks of therapy were followed by 24 weeks of treatment‐free follow‐up. All subjects were assessed for loss of hepatitis B e antigen (HBeAg), presence of hepatitis B antibody (anti‐HBe), suppression of hepatitis B virus (HBV) DNA, and normalization of serum alanine transaminase (ALT) after follow‐up. At the end of follow‐up, HBeAg was cleared in 37, 35 and 29% of patients receiving peginterferon α‐2a (40 kDa) 90, 180 and 270 μ g, respectively, compared with 25% of patients on conventional interferon α‐2a. The combined response (HBeAg loss, HBV DNA suppression, and ALT normalization) of all peginterferon α‐2a (40 kDa) doses combined was twice that achieved with conventional interferon α‐2a (24%vs 12%; P = 0.036). All treatment groups were similar with respect to frequency and severity of adverse events. These results indicate that peginterferon α‐2a (40 kDa) is superior in efficacy to conventional interferon α‐2a in chronic hepatitis B based on clearance of HBeAg, suppression of HBV DNA, and normalization of ALT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2893.2003.00450.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 475

Metadata

Authors
Cooksley, W. G. E., Piratvisuth, T., Lee, S. ‐., Mahachai, V., Chao, Y. ‐., Tanwandee, T., Chutaputti, A., Chang, W. Y., Zahm, F. E., & Pluck, N.
Venue
Journal of Viral Hepatitis
Publisher
Wiley
Published
2003-06-23
Volume
10
Issue
4
Pages
298-305
ISSN
  • 1352-0504 (ISSN-L)
  • 1365-2893
OpenAlex
W2012090731
Cited by
475
References
0
FWCI
30.49
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B. https://app.cochat.ai/papers/10.1046/j.1365-2893.2003.00450.x
The paper
Cooksley, W. G. E., Piratvisuth, T., Lee, S. ‐., Mahachai, V., Chao, Y. ‐., Tanwandee, T., Chutaputti, A., Chang, W. Y., Zahm, F. E., & Pluck, N. (2003). Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B. Journal of Viral Hepatitis. https://doi.org/10.1046/j.1365-2893.2003.00450.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.